Soluble immune checkpoints in cancer: production, function and biological significance
出版年份 2018 全文链接
标题
Soluble immune checkpoints in cancer: production, function and biological significance
作者
关键词
Immune checkpoints, T cells, Soluble receptors and ligands, Immunotherapy, Cancer
出版物
Journal for ImmunoTherapy of Cancer
Volume 6, Issue 1, Pages -
出版商
Springer Nature
发表日期
2018-11-27
DOI
10.1186/s40425-018-0449-0
参考文献
相关参考文献
注意:仅列出部分参考文献,下载原文获取全部文献信息。- Soluble Programmed Cell Death Ligand 1 as a Novel Biomarker for Nivolumab Therapy for Non–Small-cell Lung Cancer
- (2018) Yusuke Okuma et al. Clinical Lung Cancer
- Predictive Value of Soluble Programmed Death-1 for Severe Sepsis and Septic Shock During the First Week in an Intensive Care Unit
- (2018) Yongzhen Zhao et al. SHOCK
- High Serum Level of Soluble Programmed Death Ligand 1 is Associated With a Poor Prognosis in Hodgkin Lymphoma
- (2018) Xiaofang Guo et al. Translational Oncology
- New checkpoints in cancer immunotherapy
- (2017) Ling Ni et al. IMMUNOLOGICAL REVIEWS
- Early Detection of Hepatocellular Carcinoma in Patients with Hepatocirrhosis by Soluble B7-H3
- (2017) Long Zhao et al. JOURNAL OF GASTROINTESTINAL SURGERY
- Inverse correlation of soluble programmed cell death-1 ligand-1 (sPD-L1) with eosinophil count and clinical severity in allergic rhinitis patients
- (2017) Rasoul Nasiri Kalmarzi et al. ALLERGOLOGY INTERNATIONAL
- Contribution of Soluble Forms of Programmed Death 1 and Programmed Death Ligand 2 to Disease Severity and Progression in Systemic Sclerosis
- (2017) Takemichi Fukasawa et al. Arthritis & Rheumatology
- Soluble PD-L1 as a Biomarker in Malignant Melanoma Treated with Checkpoint Blockade
- (2017) Jun Zhou et al. Cancer Immunology Research
- CTLA-4 and PD-1 Pathways
- (2016) Elizabeth I. Buchbinder et al. AMERICAN JOURNAL OF CLINICAL ONCOLOGY-CANCER CLINICAL TRIALS
- Immune checkpoint inhibitors for cancer treatment
- (2016) Junsik Park et al. ARCHIVES OF PHARMACAL RESEARCH
- Upregulation of soluble B7-H3 in NSCLC-derived malignant pleural effusion: A potential diagnostic biomarker correlated with NSCLC staging
- (2016) Liwen Chen et al. CLINICA CHIMICA ACTA
- Coinhibitory Pathways in the B7-CD28 Ligand-Receptor Family
- (2016) Frank A. Schildberg et al. IMMUNITY
- PD-L1 is upregulated by EBV-driven LMP1 through NF-κB pathway and correlates with poor prognosis in natural killer/T-cell lymphoma
- (2016) Xi-wen Bi et al. Journal of Hematology & Oncology
- Soluble programmed cell death receptor-1 (sPD-1): a potential biomarker with anti-inflammatory properties in human and experimental acute respiratory distress syndrome (ARDS)
- (2016) Sean F. Monaghan et al. Journal of Translational Medicine
- Increase in soluble PD-1 is associated with prolonged survival in patients with advanced EGFR -mutated non-small cell lung cancer treated with erlotinib
- (2016) Steffen Filskov Sorensen et al. LUNG CANCER
- Enhancing T cell therapy by overcoming the immunosuppressive tumor microenvironment
- (2016) Ainhoa Arina et al. SEMINARS IN IMMUNOLOGY
- Immunogenicity to Biotherapeutics – The Role of Anti-drug Immune Complexes
- (2016) Murli Krishna et al. Frontiers in Immunology
- The PD1:PD-L1/2 Pathway from Discovery to Clinical Implementation
- (2016) Kankana Bardhan et al. Frontiers in Immunology
- Advances in Cancer Immunotherapy in Solid Tumors
- (2016) Smitha Menon et al. Cancers
- Soluble B7-H3 promotes the invasion and metastasis of pancreatic carcinoma cells through the TLR4/NF-κB pathway
- (2016) Chao Xie et al. Scientific Reports
- Novel strategies for inhibiting PD-1 pathway-mediated immune suppression while simultaneously delivering activating signals to tumor-reactive T cells
- (2015) Suzanne Ostrand-Rosenberg et al. CANCER IMMUNOLOGY IMMUNOTHERAPY
- The future of immune checkpoint therapy
- (2015) P. Sharma et al. SCIENCE
- Role of soluble programmed death-1 (sPD-1) and sPD-ligand 1 in patients with cystic echinococcosis
- (2015) YANHUA LI et al. Experimental and Therapeutic Medicine
- Hypoxia-induced soluble CD137 in malignant cells blocks CD137L-costimulation as an immune escape mechanism
- (2015) Sara Labiano et al. OncoImmunology
- Interleukin-1 is required for cancer eradication mediated by tumor-specific Th1 cells
- (2015) Ole Audun Werner Haabeth et al. OncoImmunology
- Soluble Programmed Death 1 (PD-1) Is Decreased in Patients With Immune Thrombocytopenia (ITP)
- (2014) Elif Birtas Atesoglu et al. CLINICAL AND APPLIED THROMBOSIS-HEMOSTASIS
- A role for the TIM-3/GAL-9/BAT3 pathway in determining the clinical phenotype of multiple sclerosis
- (2014) Marina Saresella et al. FASEB JOURNAL
- Targeting the alternatively spliced soluble isoform of CTLA-4: prospects for immunotherapy?
- (2014) Frank J Ward et al. Immunotherapy
- High level of soluble programmed cell death ligand 1 in blood impacts overall survival in aggressive diffuse large B-Cell lymphoma: results from a French multicenter clinical trial
- (2014) D Rossille et al. LEUKEMIA
- B7-H3 and B7-H1 expression in cerebral spinal fluid and tumor tissue correlates with the malignancy grade of glioma patients
- (2014) APARAJITA BARAL et al. Oncology Letters
- A Soluble Form of CD80 Enhances Antitumor Immunity by Neutralizing Programmed Death Ligand-1 and Simultaneously Providing Costimulation
- (2014) S. T. Haile et al. Cancer Immunology Research
- Reconstructed Adeno-Associated Virus with the Extracellular Domain of Murine PD-1 Induces Antitumor Immunity
- (2013) Osama A.O. Elhag et al. Asian Pacific Journal of Cancer Prevention
- Novel antibodies targeting immune regulatory checkpoints for cancer therapy
- (2013) Chern Siang Lee et al. BRITISH JOURNAL OF CLINICAL PHARMACOLOGY
- Clinical implications of elevated serum soluble CD137 levels in patients with acute coronary syndrome
- (2013) J Yan et al. Clinics
- The soluble isoform of CTLA-4 as a regulator of T-cell responses
- (2013) Frank J. Ward et al. EUROPEAN JOURNAL OF IMMUNOLOGY
- Expression of Programmed Death-1 (PD-1) on CD4+ and CD8+ T cells in Rheumatoid Arthritis
- (2013) Shufeng Li et al. INFLAMMATION
- In Vivo Blockade of the Programmed Cell Death-1 Pathway Using Soluble Recombinant PD-1-Fc Enhances CD4+ and CD8+ T Cell Responses but Has Limited Clinical Benefit
- (2013) P. K. Amancha et al. JOURNAL OF IMMUNOLOGY
- Soluble CD80 Restores T Cell Activation and Overcomes Tumor Cell Programmed Death Ligand 1-Mediated Immune Suppression
- (2013) S. T. Haile et al. JOURNAL OF IMMUNOLOGY
- The engagement of CTLA-4 on primary melanoma cell lines induces antibody-dependent cellular cytotoxicity and TNF-α production
- (2013) Stefania Laurent et al. Journal of Translational Medicine
- Increased PD-1 on CD4+CD28− T cell and soluble PD-1 ligand-1 in patients with T2DM: Association with atherosclerotic macrovascular diseases
- (2013) Bimin Shi et al. METABOLISM-CLINICAL AND EXPERIMENTAL
- Aberrant production of soluble inducible T-cell co-stimulator (sICOS) and soluble programmed cell death protein 1 (sPD-1) in patients with chronic hepatitis C
- (2013) DONGSHENG WANG et al. Molecular Medicine Reports
- Adenovirus Expressing Both Thymidine Kinase and Soluble PD1 Enhances Antitumor Immunity by Strengthening CD8 T-cell Response
- (2013) Seung-Pil Shin et al. MOLECULAR THERAPY
- Correction: Association of pol Diversity with Antiretroviral Treatment Outcomes among HIV-Infected African Children
- (2013) Iris Chen et al. PLoS One
- Clinical significance of the induction of macrophage differentiation by the costimulatory molecule B7-H3 in human non-small cell lung cancer
- (2013) JING SUN et al. Oncology Letters
- Increased production of circulating soluble co-stimulatory molecules CTLA-4, CD28 and CD80 in patients with rheumatoid arthritis
- (2012) Ju Cao et al. INTERNATIONAL IMMUNOPHARMACOLOGY
- SAHA/Vorinostat induces the expression of the CD137 receptor/ligand system and enhances apoptosis mediated by soluble CD137 receptor in a human breast cancer cell line
- (2012) DANIELA BELLAROSA et al. INTERNATIONAL JOURNAL OF ONCOLOGY
- Enhancement of Membrane B7-H3 Costimulatory Molecule but Reduction of Its Soluble Form in Multiple Sclerosis
- (2012) Juean Jiang et al. JOURNAL OF CLINICAL IMMUNOLOGY
- A Soluble Form of CTLA-4 Is Present in Paediatric Patients with Acute Lymphoblastic Leukaemia and Correlates with CD1d+ Expression
- (2012) Rita Simone et al. PLoS One
- Development of a sandwich ELISA for evaluating soluble PD-L1 (CD274) in human sera of different ages as well as supernatants of PD-L1+ cell lines
- (2011) Yongjing Chen et al. CYTOKINE
- The Soluble CTLA-4 Splice Variant Protects From Type 1 Diabetes and Potentiates Regulatory T-Cell Function
- (2011) K. D. Gerold et al. DIABETES
- Admission levels of soluble CD137 are increased in patients with acute pancreatitis and are associated with subsequent complications
- (2011) Zhe Shao et al. EXPERIMENTAL AND MOLECULAR PATHOLOGY
- Soluble B7-H1: Differences in production between dendritic cells and T cells
- (2011) Xavier Frigola et al. IMMUNOLOGY LETTERS
- Enhancement of Vaccine-induced Primary and Memory CD8+ T-cell Responses by Soluble PD-1
- (2011) Mi-Young Song et al. JOURNAL OF IMMUNOTHERAPY
- Potential role of soluble B7-H3 in liver immunopathogenesis during chronic HBV infection
- (2011) Y. Luan et al. JOURNAL OF VIRAL HEPATITIS
- Aberrant production of soluble co-stimulatory molecules CTLA-4 and CD28 in patients with chronic hepatitis B
- (2011) Ju Cao et al. MICROBIAL PATHOGENESIS
- B7-H3 Augments the Inflammatory Response and Is Associated with Human Sepsis
- (2010) G. Zhang et al. JOURNAL OF IMMUNOLOGY
- Detection and Quantitation of Soluble B7-H3 in Expressed Prostatic Secretions: A Novel Marker in Patients With Chronic Prostatitis
- (2010) Xuedong Wei et al. JOURNAL OF UROLOGY
- CD137, implications in immunity and potential for therapy
- (2009) Elaine Thum Frontiers in Bioscience-Landmark
- Soluble PD-1 is Associated with Aberrant Regulation of T Cells Activation in Aplastic Anemia
- (2009) Haijing Wu et al. IMMUNOLOGICAL INVESTIGATIONS
- Increased production of soluble CTLA-4 in patients with spondylarthropathies correlates with disease activity
- (2009) Éric Toussirot et al. ARTHRITIS RESEARCH & THERAPY
- Soluble CD276 (B7-H3) is released from monocytes, dendritic cells and activated T cells and is detectable in normal human serum
- (2008) Guangbo Zhang et al. IMMUNOLOGY
- Anti–Cytotoxic T-Lymphocyte Antigen-4 Antibody: The First in an Emerging Class of Immunomodulatory Antibodies for Cancer Treatment
- (2008) Lawrence Fong et al. JOURNAL OF CLINICAL ONCOLOGY
Add your recorded webinar
Do you already have a recorded webinar? Grow your audience and get more views by easily listing your recording on Peeref.
Upload NowCreate your own webinar
Interested in hosting your own webinar? Check the schedule and propose your idea to the Peeref Content Team.
Create Now